Neuren Launches Pioneering Phase 3 Trial for Rare Phelan-McDermid Syndrome Treatment

• First patient dosed in Neuren’s Phase 3 Koala trial for Phelan-McDermid syndrome
• Trial involves approximately 160 children aged 3 to 12 years
• NNZ-2591 has Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA
• Multiple US trial sites activating with strong patient interest and waitlists